Efficacy of abiraterone combined with flutamide on prostate cancer patients and its effect on serum miR-493-5p and miR-195-5p

Yang,Chunyan; Dai,Yanling; Pang,Shuhua; Guo,Xiaomin

doi:10.3892/ol.2020.11719

Efficacy of abiraterone combined with flutamide on prostate cancer patients and its effect on serum miR-493-5p and miR-195-5p

Authors:
- Chunyan Yang
- Yanling Dai
- Shuhua Pang
- Xiaomin Guo
View Affiliations

Affiliations: Department of Pharmacy, Chuxiong Medical College, Chuxiong, Yunnan 675000, P.R. China, Laboratory Department, Chuxiong Medical College, Chuxiong, Yunnan 675000, P.R. China, Clinical Laboratory, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China, School of Nursing, Chuxiong Medical College, Chuxiong, Yunnan 675000, P.R. China
Published online on: June 9, 2020 https://doi.org/10.3892/ol.2020.11719
Pages: 1922-1930
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Efficacy of abiraterone combined with flutamide on patients with prostate cancer (PCa) and its effect on levels of miR-493-5p and miR-195-5p contained in serum were investigated. The medical records of 146 PCa patients admitted to Longhua Hospital Shanghai University of Traditional Chinese Medicine from January 2011 to December 2013 were selected. Eighty-four patients were treated with abiraterone combined with flutamide as a study group, 62 patients were treated with abiraterone alone as a control group. The curative effect, adverse reactions, quality of life and five-year overall survival (OS) of the two groups were compared. The serum prostate-specific antigen (PSA) level was measured by radioimmunoassay at 3 days (T1) before treatment, 1 month (T2), 2 months (T3), and 6 months (T4) after treatment, and the relative expression of miR-493-5p and miR-195-5p in serum were detected by qRT-PCR. The total effective rate of the study group was significantly higher than that of the control group (P<0.05). The total incidence of toxic and side effects in the study group was significantly lower than that in the control group (P<0.05). The improvement rate of quality of life in the study group was significantly higher than that in the control group (P<0.05). OS in the study group was significantly higher than that in the control group at 5 years (P<0.05). There was no significant difference in serum PSA level between the two groups at T1 (P>0.05); there was no significant difference in the relative expression of miR-493-5p and miR-195-5p between the two groups at T1 (P>0.05). In conclusion, abiraterone combined with flutamide has better curative effect and lower incidence of adverse reactions in patients with metastatic castration-resistant PCa (CRPC) than abiraterone alone, and can increase the expression levels of miR-493-5p and miR-195-5p in patient serum.

View Figures

View References

1	Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, et al: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 44:1258–1268. 2017. View Article : Google Scholar : PubMed/NCBI
2	Watson PA, Arora VK and Sawyers CL: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI
3	Yang Y, Chen R, Sun T, Zhao L, Liu F, Ren S, Wang H, Lu X, Gao X, Xu C, et al: Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer. Curr Oncol. 26:e39–e47. 2019. View Article : Google Scholar : PubMed/NCBI
4	Kambale PR, Haldar D, Kabi BC and Kambale KP: Study of vitamin D receptor gene polymorphism (FokI, TaqI and ApaI) among prostate cancer patients in North India. J Clin Diagn Res. 11:BC05–BC08. 2017.PubMed/NCBI
5	Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM and van Erp NP: Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: Abiraterone acetate and enzalutamide. Clin Pharmacokinet. 55:1369–1380. 2016. View Article : Google Scholar : PubMed/NCBI
6	Yasui M, Uemura K, Yoneyama S, Kawahara T, Hattori Y, Teranishi JI, Inoue M, Ohta JI, Yokomizo Y, Yao M, et al: Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer. Jpn J Clin Oncol. 46:1042–1046. 2016. View Article : Google Scholar : PubMed/NCBI
7	Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, et al: Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 28:1489–1495. 2010. View Article : Google Scholar : PubMed/NCBI
8	de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al COU-AA-301 Investigators, : Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar
9	Iguchi T, Tamada S, Kato M, Yasuda S, Otoshi T, Hamada K, Yamasaki T and Nakatani T: Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: A retrospective study. Int J Clin Oncol. 24:848–856. 2019. View Article : Google Scholar : PubMed/NCBI
10	Fukasawa S, Suzuki H, Kawaguchi K, Noguchi H, Enjo K, Tran N, Todd M, Fizazi K and Matsubara N: Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: A subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. Jpn J Clin Oncol. 48:1012–1021. 2018. View Article : Google Scholar : PubMed/NCBI
11	Nie W, Ge HJ, Yang XQ, Sun X, Huang H, Tao X, Chen WS and Li B: LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett. 371:99–106. 2016. View Article : Google Scholar : PubMed/NCBI
12	Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P: miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene. 34:3240–3250. 2014. View Article : Google Scholar : PubMed/NCBI
13	Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E and Quek RGW: Patterns of bicalutamide use in prostate cancer treatment: A U.S. real-world analysis using the SEER-Medicare database. Adv Ther. 35:1438–1451. 2018. View Article : Google Scholar : PubMed/NCBI
14	Zhao L, Feng X, Song X, Zhou H, Zhao Y, Cheng L and Jia L: miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4. Oncol Rep. 36:1007–1015. 2016. View Article : Google Scholar : PubMed/NCBI
15	Wang G, Fang X, Han M, Wang X and Huang Q: MicroRNA-493-5p promotes apoptosis and suppresses proliferation and invasion in liver cancer cells by targeting VAMP2. Int J Mol Med. 41:1740–1748. 2018.PubMed/NCBI
16	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
17	Tamada S, Iguchi T, Kato M, Asakawa J, Kita K, Yasuda S, Yamasaki T, Matsuoka Y, Yamaguchi K, Matsumura K, et al: Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer. Oncotarget. 9:36966–36974. 2018. View Article : Google Scholar : PubMed/NCBI
18	Teoh JY, Ng CF and Poon DM: Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective. Asia Pac J Clin Oncol. 14 (Suppl 5):5–8. 2018. View Article : Google Scholar : PubMed/NCBI
19	Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al: Integrative clinical genomics of advanced prostate cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI
20	Mittal RD, Mishra DK, Srivastava P, Manchanda P, Bid HK and Kapoor R: Polymorphisms in the vitamin D receptor and the androgen receptor gene associated with the risk of urolithiasis. Indian J Clin Biochem. 25:119–126. 2010. View Article : Google Scholar : PubMed/NCBI
21	Dong L, Zieren RC, Xue W, de Reijke TM and Pienta KJ: Metastatic prostate cancer remains incurable, why? Asian J Urol. 6:26–41. 2019. View Article : Google Scholar : PubMed/NCBI
22	Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ and Bjartell A: Tumor markers in prostate cancer I: Blood-based markers. Acta Oncol. 50 (Suppl 1):61–75. 2011. View Article : Google Scholar : PubMed/NCBI
23	Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, Zafeiriou Z, Sumanasuriya S, Smith AD, Mehra N, et al: Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer. Eur Urol. 70:724–731. 2016. View Article : Google Scholar : PubMed/NCBI
24	Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, et al: Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 36:1389–1395. 2018. View Article : Google Scholar : PubMed/NCBI
25	Nagai T, Naiki T, Iida K, Etani T, Ando R, Hamamoto S, Sugiyama Y, Akita H, Kubota H, Hashimoto Y, et al: Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade. Prostate Int. 6:18–23. 2018. View Article : Google Scholar : PubMed/NCBI
26	Xu L, Chen J, Liu W, Liang C, Hu H and Huang J: Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer. Asian J Urol. 6:91–98. 2019. View Article : Google Scholar : PubMed/NCBI
27	Ito Y and Sadar MD: Enzalutamide and blocking androgen receptor in advanced prostate cancer: Lessons learnt from the history of drug development of antiandrogens. Res Rep Urol. 10:23–32. 2018.PubMed/NCBI
28	Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, et al: Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 14:1193–1199. 2013. View Article : Google Scholar : PubMed/NCBI
29	Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, et al LATITUDE investigators, : Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 377:352–360. 2017. View Article : Google Scholar : PubMed/NCBI
30	Zhao JG, Liu JD, Shen PF, Tang X, Sun GX, Zhang XM, Chen JR, Shu KP, Shi M and Zeng H: Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: A real-world retrospective study. Asian J Androl. 20:545–550. 2018. View Article : Google Scholar : PubMed/NCBI
31	Wang S, Wang X, Li J, Meng S, Liang Z, Xu X, Zhu Y, Li S, Wu J, Xu M, et al: c-Met, CREB1 and EGFR are involved in miR-493-5p inhibition of EMT via AKT/GSK-3β/Snail signaling in prostate cancer. Oncotarget. 8:82303–82313. 2017. View Article : Google Scholar : PubMed/NCBI
32	Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195-5 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
33	Linder S, van der Poel HG, Bergman AM, Zwart W and Prekovic S: Enzalutamide therapy for advanced prostate cancer: Efficacy, resistance and beyond. Endocr Relat Cancer. 26:R31–R52. 2018.PubMed/NCBI